DAPA-HF trial signals the birth of ‘diabetic cardiology’ and more

[no abstract - showing first paragraph of article]Sodium-glucose co-transporter-2 (SGLT2) inhibitors are relatively new class of antihyperglycemic medication that is well established in the management of type 2 diabetes mellitus (DM). It has a unique mechanism of action that targets the kidneys through inhibiting 90% of glucose reabsorption.